Indivior (Nasdaq: INDV) study supports 300 mg SUBLOCADE dose for fentanyl-heavy opioid use cases

Indivior PLC (NASDAQ: INDV) has released clinical trial results in JAMA Network Open demonstrating that its extended-release buprenorphine product, SUBLOCADE, significantly reduced opioid use and improved abstinence outcomes across both 100 mg and 300 mg monthly doses. However, the study’s post-hoc analyses further revealed that the higher 300 mg dose may deliver superior results specifically in high-frequency fentanyl users—a population that has remained particularly challenging to treat within the current opioid epidemic context.

This updated evidence base strengthens Indivior’s positioning in opioid use disorder (OUD) treatment, particularly as fentanyl reshapes the risk profile of OUD patients. For clinicians, regulators, and payers alike, the data could influence treatment protocols, reimbursement models, and resource prioritization in tackling the opioid crisis.

How does Indivior’s new study shift clinical treatment expectations for opioid use disorder?

The key finding of the randomized, double-blind study is that both 100 mg and 300 mg monthly doses of extended-release buprenorphine substantially reduced opioid use in patients with moderate-to-severe OUD—from a median of over 43 uses per week at screening to fewer than three by week three. That result alone reaffirms the product’s clinical viability in real-world scenarios.

However, what elevates the trial’s relevance is its post-hoc analysis, which identifies high-frequency fentanyl users as a distinct responder group. Participants who used fentanyl daily, or at least 14 times per week, achieved significantly higher abstinence rates with the 300 mg maintenance dose compared to the 100 mg group. While this segment was not the primary focus of the trial and the findings are considered exploratory, they reflect a growing need for nuanced dosing strategies that address varying opioid potencies and usage patterns in different patient subsets.

With the rising presence of synthetic opioids like fentanyl in illicit drug markets—drugs that are 50 to 100 times more potent than morphine—traditional dosing frameworks may be insufficient. Indivior’s findings support a more differentiated treatment model and could push clinical guidelines toward stratified approaches based on patient opioid type and use frequency.

What are the commercial implications for SUBLOCADE amid increasing payer scrutiny?

For Indivior, SUBLOCADE represents a long-term strategic pillar. Extended-release buprenorphine, delivered as a once-monthly injection, simplifies treatment logistics and aligns well with payer demands for adherence and reduced misuse risk. By removing the need for daily supervision—as is typical with oral or sublingual buprenorphine—SUBLOCADE also reduces potential diversion, a major concern in traditional OUD pharmacotherapy.

Payers are increasingly favoring long-acting injectables in behavioral health conditions, particularly when paired with evidence of real-world abstinence. The newly published trial adds weight to SUBLOCADE’s case in payer negotiations, particularly for high-risk fentanyl cohorts who may otherwise cycle through multiple less-effective options. It is reasonable to expect Indivior to leverage these findings in its ongoing discussions with Medicaid programs, commercial insurers, and integrated delivery networks.

In addition, the data could help justify coverage of the higher 300 mg dose—currently priced above the 100 mg version—especially if further studies validate the fentanyl-specific benefits in larger populations. From a revenue perspective, dose optimization may serve as a hidden growth lever within the existing product base.

How does this reinforce Indivior’s positioning versus peers in the OUD treatment market?

Indivior’s closest competitors in the OUD space include Alkermes with VIVITROL (extended-release naltrexone), Braeburn’s Brixadi (buprenorphine weekly and monthly injections), and generics of sublingual buprenorphine-naloxone. Each has differentiated profiles, but none yet demonstrate a post-hoc effect tied specifically to fentanyl usage patterns in a randomized trial.

SUBLOCADE’s advantage lies in its depot formulation and its REMS (Risk Evaluation and Mitigation Strategy) distribution controls, which make it less susceptible to diversion and easier to manage in correctional or clinic-based settings. If high-dose regimens prove more effective in fentanyl users, SUBLOCADE may emerge as the default option in these cases—both clinically and administratively.

This could tilt market share further in Indivior’s favor, particularly among institutional buyers (prisons, treatment centers, and managed Medicaid providers), who often seek a balance between cost containment, safety, and treatment durability.

What clinical and regulatory risks still surround the use of high-dose extended-release buprenorphine?

Despite the positive abstinence data, the 300 mg dose of SUBLOCADE comes with higher rates of injection site reactions. While these events were reported as mild to moderate and did not cause discontinuation in the trial, they may still raise questions for regulators and treatment providers, particularly in populations already vulnerable to adherence issues or mistrust in injectable therapies.

The exploratory nature of the post-hoc analysis also limits the strength of the conclusions that can be drawn. Because the fentanyl-specific benefits were not part of the pre-specified statistical plan, any clinical guidelines or label revisions would require replication or targeted trials focused on this subgroup.

From a regulatory standpoint, the current SUBLOCADE label already carries a boxed warning against intravenous administration, due to the formulation forming a solid mass that can cause serious harm. Any attempt to revise dose-related guidance or promote off-label high-dose benefits in fentanyl users would face scrutiny under current FDA frameworks.

Still, the trial offers a credible rationale for future Phase 4 studies or real-world evidence programs aimed at quantifying the benefits of dose stratification in fentanyl-dominant populations.

How could this influence public health strategy amid the ongoing U.S. opioid crisis?

This study arrives at a time when fentanyl continues to drive overdose deaths in the United States, contributing to over 70,000 of the estimated 107,000 drug overdose deaths in 2023. The Centers for Disease Control and Prevention (CDC), Substance Abuse and Mental Health Services Administration (SAMHSA), and state-level programs are actively seeking differentiated solutions that can be scaled in high-burden geographies.

Long-acting injectables like SUBLOCADE are increasingly viewed as part of the answer—not just for their clinical benefits, but for the potential system-level efficiency they offer. Reduced clinic visits, lowered diversion risk, and improved adherence translate into lower total cost of care when measured against emergency room visits, inpatient detox, and recidivism.

With a focused fentanyl dosing strategy, Indivior could support public health objectives that go beyond individual treatment success and address systemic strain on emergency services and behavioral health infrastructure.

How is Indivior likely to capitalize on these results in future commercial and R&D plans?

From a commercial standpoint, Indivior is likely to use this data to deepen engagement with public sector payers, correctional health services, and federally qualified health centers. The findings also open the door to differentiated messaging for care providers treating fentanyl-heavy caseloads.

From an R&D angle, the company may seek to conduct additional trials or retrospective claims analysis to confirm the high-dose benefit in fentanyl subpopulations. A formal prospective study powered to evaluate dose-response in fentanyl-only users could unlock stronger regulatory and commercial positioning.

If Indivior pursues this pathway, the company could move toward a segmented treatment algorithm: standard 100 mg for typical OUD and 300 mg targeted for high-potency opioid users. This aligns with the broader industry shift toward personalized addiction medicine, an area still in early development.

What are the key takeaways from Indivior’s SUBLOCADE study and its implications for the OUD treatment landscape?

• Indivior’s study confirms that extended-release buprenorphine significantly reduces opioid use and improves abstinence in moderate-to-severe OUD.

• Post-hoc analysis suggests the 300 mg monthly dose may be more effective than the 100 mg dose in individuals with high-frequency fentanyl use.

• These results could influence payer policies and justify higher-dose reimbursement, especially in high-risk patient subgroups.

• SUBLOCADE’s depot formulation and REMS program continue to offer strategic advantages over oral and sublingual competitors.

• Regulatory caution remains due to the exploratory nature of the findings and the increased rate of injection site reactions.

• The data may support future public health programs targeting synthetic opioid users with differentiated dosing regimens.

• Indivior could build on these findings through targeted Phase 4 studies or health system collaborations.

• The company’s position in the OUD treatment market may strengthen if the 300 mg dose is validated for fentanyl-specific cases.